Oxidative Stress and Amyloidogenesis

About the Research Project
Program
Award Type
Pilot
Award Amount
$187,500
Active Dates
April 01, 2008 - September 30, 2010
Grant ID
A2008123
Goals
Oxidative stress and amyloid fibril formation are consistent major themes among processes thought to be involved in the pathogenesis of Alzheimer’s disease. However, a mechanistic link between these two processes has not been defined. The research being proposed will probe human brain tissues and animal models of Alzheimer’s disease for evidence of a specific chemical mechanism that will be amenable to therapeutic intervention.
Summary
Oxidative stress and amyloid fibril formation are consistent major themes among processes thought to be involved in the pathogenesis of Alzheimer’s disease. However, a mechanistic link between these two processes has not been defined. The research being proposed will probe human brain tissues and animal models of Alzheimer’s disease for evidence of a specific chemical mechanism that will be amenable to therapeutic intervention.
Grants
Related Grants
Alzheimer's Disease Research
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015

Principal Investigator
Guojun Bu, PhD
Alzheimer's Disease Research
Synergistic Effects of Biological Sex and Sleep Loss in an AD Mouse Model
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Mallar Chakravarty, PhD
Synergistic Effects of Biological Sex and Sleep Loss in an AD Mouse Model
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Mallar Chakravarty, PhD
Alzheimer's Disease Research
Regulatory Mechanisms Underlying Endosomal Targeting of SORL1
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Olav Andersen, PhD
Regulatory Mechanisms Underlying Endosomal Targeting of SORL1
Active Dates
January 01, 2025 - December 31, 2026

Principal Investigator
Olav Andersen, PhD